Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16185164 | 0.94 | GRM5 (0.43) | S1PR1MAPK14FFAR1GRM5METAP2 | |
| SCHEMBL16185134 | 0.91 | FFAR1 (0.47) | S1PR1MAPK14FFAR1GRM5METAP2 | |
| SCHEMBL14474182 | 0.90 | ABCB1 (0.47) | MAPK14FFAR1GRM5METAP2METAP1 | |
| SCHEMBL14474192 | 0.89 | CHRNA7 (0.43) | S1PR1CHRNA7GRM5LMNAKDM4E | |
| SCHEMBL16185147 | 0.89 | FFAR1 (0.43) | S1PR1CHRNA7MAPK14FFAR1GRM5 | |
| SCHEMBL16185154 | 0.89 | GRM5 (0.42) | S1PR1CHRNA7MAPK14FFAR1GRM5 | |
| SCHEMBL14475260 | 0.88 | GRM5 (0.42) | S1PR1MAPK14FFAR1GRM5METAP2 | |
| SCHEMBL16185141 | 0.88 | CHRNA7 (0.42) | S1PR1CHRNA7GRM5LMNAKDM4E | |
| SCHEMBL16185142 | 0.87 | CHRNA7 (0.42) | S1PR1CHRNA7LMNASMN1; SMN2 | |
| SCHEMBL14474202 | 0.87 | CHRNA7 (0.45) | CHRNA7MAPK14GRM5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| WO-2013003586-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | S1PR1 3969/4885CHRNA7 349/4885MAPK14 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.